87 related articles for article (PubMed ID: 18633257)
1. [Comparative survey on current status and the differences of treatment using modified FOLFOX6 regimen in patients with colorectal cancer in two general hospitals].
Kitada N; Morita S; Morimoto S; Yamasaki H; Fujii C; Anami S; Fukunaga M; Furukawa H; Takara K; Yokoyama T; Watari M
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1175-80. PubMed ID: 18633257
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience.
Shimizu T; Satoh T; Tamura K; Ozaki T; Okamoto I; Fukuoka M; Nakagawa K
Int J Clin Oncol; 2007 Jun; 12(3):218-23. PubMed ID: 17566846
[TBL] [Abstract][Full Text] [Related]
3. The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen.
Nishioka M; Shimada M; Kurita N; Iwata T; Morimoto S; Yoshikawa K; Higashijima J; Miyatani T; Kono T
Int J Clin Oncol; 2011 Aug; 16(4):322-7. PubMed ID: 21258836
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
5. [Effect of withdrawal of 5-fluorouracil bolus administration on recovery from neutropenia in colorectal cancer patients treated with mFOLFOX6 chemotherapy-comparison with total dosage reduction].
Ueda H; Demizu M; Oosawa M; Chihara S; Nakanishi Y; Maeda C; Yano K; Kimura F; Iwakawa S
Gan To Kagaku Ryoho; 2009 May; 36(5):789-93. PubMed ID: 19461179
[TBL] [Abstract][Full Text] [Related]
6. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
[TBL] [Abstract][Full Text] [Related]
7. [A feasibility study of oxaliplatin (L-OHP) in combination with infusional 5-FU/l-LV (FOLFOX4 regimen) for advanced colorectal cancer].
Suenaga M; Nishina T; Hyodo I; Munakata M; Koizumi W; Mishima H; Sato A; Mizunuma N; Hatake K
Gan To Kagaku Ryoho; 2008 Feb; 35(2):255-60. PubMed ID: 18281761
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
[TBL] [Abstract][Full Text] [Related]
9. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
10. Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.
Ajima H; Ogata H; Fujita K; Miwa K; Sunakawa Y; Mizuno K; Ishida H; Yamashita K; Nakayama H; Kawara K; Takahashi H; Sasaki Y
Jpn J Clin Oncol; 2010 Jul; 40(7):634-8. PubMed ID: 20587616
[TBL] [Abstract][Full Text] [Related]
11. L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways.
Yehia R; Saleh S; El Abhar H; Saad AS; Schaalan M
Toxicol Appl Pharmacol; 2019 Feb; 365():41-50. PubMed ID: 30592963
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
[TBL] [Abstract][Full Text] [Related]
13. Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer.
Inoue N; Ishida H; Sano M; Kishino T; Okada N; Kumamoto K; Ishibashi K
Int J Clin Oncol; 2012 Aug; 17(4):341-7. PubMed ID: 21833683
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies.
Ohtani H; Arimoto Y; Nishio K; Kanamiya Y; Oba H; Adachi K; Shintani M; Nakamura R; Yui S
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1769-74. PubMed ID: 18931586
[TBL] [Abstract][Full Text] [Related]
15. A multicenter phase-II study of 5-FU, leucovorin and oxaliplatin (FOLFOX6) in patients with pretreated metastatic colorectal cancer.
Kato K; Inaba Y; Tsuji Y; Esaki T; Yoshioka A; Mizunuma N; Mizuno T; Kusaba H; Fujii H; Muro K; Shimada Y; Shirao K
Jpn J Clin Oncol; 2011 Jan; 41(1):63-8. PubMed ID: 20819832
[TBL] [Abstract][Full Text] [Related]
16. Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: a retrospective study of 69 male patients receiving modified FOLFOX6 therapy.
Tatsushima Y; Egashira N; Narishige Y; Fukui S; Kawashiri T; Yamauchi Y; Oishi R
Biomed Pharmacother; 2013 Feb; 67(1):39-42. PubMed ID: 23206755
[TBL] [Abstract][Full Text] [Related]
17. [Retrospective analysis of FOLFOX4 neurotoxicity for recovery from advanced colorectal cancer].
Matsuda M; Matsusaka S; Kuboki Y; Itimura T; Ogura M; Suenaga M; Syouji D; Watanabe C; Chin K; Mizunuma N; Hatake K
Gan To Kagaku Ryoho; 2008 Mar; 35(3):461-6. PubMed ID: 18347395
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic effects of FOLFOX6 versus TLF regimen as the first line chemotherapy for advanced gastric cancer].
Yu HB; Xian HB; Deng YM; Li LL
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Oct; 30(10):2373-6. PubMed ID: 20965850
[TBL] [Abstract][Full Text] [Related]
19. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]